Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of egfr mutation and its subtypes in lung adenocarcinoma

Pathology and Oncology Research

Volumn 20, Issue 2, 2014, Pages 445-451

  Lu, Rong Li ^a   Hu, Cheng Ping ^a   Yang, Hua Ping ^a   Li, Yuan Yuan ^a   Gu, Qi Hua ^a   Wu, Lielin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor (EGFR); Erlotinib; Exon 19 deletions(del 19); Exon 21 point mutation(L858R); Gefitinib; Lung adenocarcinoma(LAC)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; POINT MUTATION; PROGRESSION FREE SURVIVAL; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; VERY ELDERLY; ADENOCARCINOMA; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898817748     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9715-0     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367-1380
3. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
4. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128
5. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139
6. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500
7. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
8. Yang CH, Yu CJ, Shih JY et al (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26(16):2745-2753
9. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
10. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527-1537
11. Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132
12. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101(36):13306-13311
13. Taron M, Ichinose Y, Rosell R et al (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11(16):5878-5885
14. Uramoto H, Sugio K, Oyama T et al (2006) Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51(1):71-77
15. Li M, Yin Z, Guan P et al (2008) XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer 62(2):145-151
16. Ko YC, Cheng LS, Lee CH et al (2000) Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 151(2):140-147
17. Metayer C, Wang Z, Kleinerman RA et al (2002) Cooking oil fumes and risk of lung cancer in women in rural Gansu. China Lung Cancer 35(2):111-117
18. Lin Y, Cai L (2012) Environmental and dietary factors and lung cancer risk among Chinese women: a case-control study in Southeast China. Nutr Cancer 64(4):508-514
19. Yang HH, Chien SM, Lee HL et al (2007) Emission of trans,trans-2,4- decadienal from restaurant exhausts to the atmosphere. Atmos Environ, 41: 5327-5333
20. Chang LW, Lo WS, Lin P (2005) Trans, trans-2,4-decadienal, a product found in cooking oil fumes, induces cell proliferation and cytokine production due to reactive oxygen species in human bronchial epithelial cells. Toxicol Sci 87(2):337-343
21. Meng-hong S, Fei Y, Lei S (2011) Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types. Chinese J Pathol 40(10):655-659
22. Miao-Jin F, Hai-Gang L, Zhi-Qiang L et al (2011) Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer. Chinese J Pathol 40(10):679-682
23. Tomizawa Y, Iijima H, Sunaga N et al (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11(19 Pt 1):6816-6822
24. Tam IY, Chung LP, Suen WS et al (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12(5):1647-1653
25. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
26. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118(2):257-262
27. Kim ST, Lee J, Kim JH et al (2010) Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116(12):3025-3033
28. Kim ST, Uhm JE, Lee J et al (2012) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75(1):82-88